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Abstract 
 Intraperitoneal (IP) administration of nano-sized delivery vehicles containing small interfering 
RNA (siRNA) is recently gaining attention as an alternative route for the efficient treatment of 
peritoneal carcinomatosis. The colloidal stability of nanomatter following IP administration has, 
however, not been thoroughly investigated yet. Here, enabled by advanced microscopy methods 
such as Single Particle Tracking (SPT) and Fluorescence Correlation Spectroscopy (FCS), we 
follow the aggregation and cargo release of nano-scaled systems directly in peritoneal fluids from 
healthy mice and ascites fluid from a patient diagnosed with peritoneal carcinomatosis. The 
colloidal stability in the peritoneal fluids was systematically studied in function of the charge 
(positive or negative) and Poly-Ethylene Glycol (PEG) degree of liposomes and polystyrene 
nanoparticles, and compared to human serum. Our data demonstrate strong aggregation of cationic 
and anionic nanoparticles in the peritoneal fluids, while only slight aggregation was observed for 
the PEGylated ones. PEGylated liposomes, however, lead to a fast and premature release of siRNA 
cargo in the peritoneal fluids. Based on our observations, we reflect on how to tailor improved 
delivery systems for IP therapy.   
Keywords: Drug delivery, Aggregation, Peritoneal Carcinomatosis, Intraperitoneal 
administration, Release, siRNA 
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1. Introduction 
Peritoneal metastases are one of the major causes of death in patients diagnosed with ovarian 
cancer [1]. Also in colorectal cancer, cancer cells often migrate to the abdomen where they spread 
and form peritoneal carcinomatosis [2]. The often late stage of discovery of peritoneal metastases, 
which can spread over the entire surface of the peritoneum (~2 m²), make the treatment very 
difficult. This fact is well-demonstrated from clinical trials indicating the low median survival of 
patients diagnosed with peritoneal carcinomatosis [3].  
 Current treatment of peritoneal carcinomatosis involves removing the majority of 
peritoneal metastases (cytoreductive surgery) followed by intravenous (IV) administration of 
chemotherapeutic agents such as oxaliplatin in combination with 5-fluorouracil or leucovorin [4, 
5] to kill remaining tumor cells. Also platinum-based (i.e. oxaliplatin, cisplatin) chemotherapeutics 
in combination with paclitaxel [6, 7] are used. Unfortunately, the majority of the patients develop 
disease recurrence [8, 9]. Therefore, more efficient post-surgical strategies to kill remaining tumor 
cells are needed [10]. In this context, intraperitoneal (IP) administration of chemotherapeutics has 
shown to be superior over the intravenous route [11, 12], particularly due to the ability to maintain 
high concentrations of cytotoxic agents in the peritoneal cavity [13]. Also, promising data have 
resulted from clinical trials evaluating hyperthermic intraperitoneal chemoperfusion (HIPEC) 
immediately after cytoreductive surgery [14, 15]. HIPEC involves flushing the peritoneal cavity 
with chemotherapeutic agents at an elevated temperature of 41-42°C. It is hypothesized that 
HIPEC is more efficacious compared to conventional intraperitoneal therapy since it not only takes 
advantage of the hyperthermic effect, but also enables distribution of the drug in all parts of the 
peritoneal cavity [16]. Nevertheless, the efficacy of HIPEC is still controversial as several studies 
claim that no synergistic effect exists between the anti-cancer agent and the hyperthermia [15, 17].  
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 One strategy to improve the anticancer effect upon cytoreductive surgery is to use 
specialized drug delivery systems (DDSs) with the ability to reside in the peritoneal cavity for a 
prolonged period of time. Interestingly, recent in vivo data suggest that the intraperitoneal 
administration of DDSs that release chemotherapeutics results in an enhanced body distribution in 
general, and on the intratumoral level in particular [18]. Also the delivery of small interfering RNA 
(siRNA) for the treatment of ovarian cancer and peritoneal carcinomatosis has recently attracted 
considerable attention [19].  siRNAs are small (20-21 nucleotides) double stranded RNA 
molecules that can downregulate specific protein production.. siRNA has the benefit that it can 
target genes which are specific for tumor cells, leaving healthy, non-tumor tissue unaffected. 
Interestingly, carriers for combinatorial therapy of (specific) siRNA and conventional (non-
specific) anti-cancer drugs (e.g. paclitaxel (PTX) or doxorubicin (DOX)) have been reported to 
result in some benefits compared to each one alone [20].  
 In the past few years, different DDSs were evaluated for IP administration [21, 22], Among 
them are targeted nanocarriers [23], nanoparticles for intraperitoneal gene delivery [24], micelles 
[25], microparticle [26, 27] and hydrogels for sustained release in the peritoneal cavity [28-30]. 
For nanosized drug carriers, the state of aggregation and the release profile following IP 
administration may play a crucial role in their delivery performance. Indeed, the colloidal stability 
of nanocarriers influences e.g. the internalization of the cargo into cancer cells, and thus may alter 
the expected anti-tumor efficacy. Following administration, nano-carriers tend to bind/interact 
with various components that are present in biofluids [31], including proteins and enzymes 
forming the so called ‘protein corona’ [32, 33]. For instance, recent reports suggest that the 
targeting capability of ligands conjugated to nanomaterials is lost by adsorption of a protein corona 
to their surface [34, 35]. Increasing our knowledge on the relation between the physicochemical 
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properties of delivery systems and their obtained therapeutic effect is crucial. Since the route of 
administration plays a major role in whether or not certain carriers will work, each carrier should 
be optimized for the in vivo situation where it is intended to be used, e.g. the intraperitoneal fluid 
in the case of IP delivery. Although several studies have addressed the colloidal stability of 
nanoparticles in biofluids like blood, plasma and serum [36, 37], the physicochemical behavior of 
delivery vehicles in terms of aggregation and release of cargo in peritoneal fluids has not been 
investigated yet.    
 The main objective of this study is to provide insight in the requirements for IP delivery 
systems in terms of charge and PEGylation degree, to be colloidally stable and to have an optimal 
release profile in the peritoneal fluid. Herein, for the first time, we study the aggregation of 
polystyrene (PS) nanoparticles and liposomal formulations in peritoneal fluid from healthy mice 
(transsudate) and ascites fluid (exudate) from a patient diagnosed with peritoneal carcinomatosis. 
Additionally, we study the release profile of liposomal formulations carrying siRNA in the 
peritoneal fluids. For this purpose, we utilize state of the art fluorescence techniques that were 
previously developed in our laboratory, namely Single Particle Tracking (SPT) and Fluorescence 
Correlation Spectroscopy (FCS) to respectively gain information on the aggregation of 
nanoparticles and the release of siRNA in undiluted biofluids [36, 38]. The results are compared 
to measurements of the same nanoparticles dispersed in human serum. 
2. Materials and Methods 
2.1 Materials 
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(2,3-Dioleoyloxy-propyl)-trimethylammonium-chloride (DOTAP) and 1,2-Dioleoyl-sn-glycero-
3-phosphoethanolamine (DOPE) were purchased from Corden Pharma LLC (Liestal, 
Switzerland). 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] 
(DSPE-PEG) was purchased from Avanti Polar Lipids  (Alabaster, AL, USA). Chloroform, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), N-hydroxysulfosuccinimide (Sulfo-
NHS), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), 
Dimethylethylenediamine (DMEDA) and sodium chloride (NaCl) were purchased from Sigma 
Aldrich (Bornem, Belgium). Yellow-green fluorescent (λex= 505 nm, λem= 515 nm) carboxylated 
PS FluoSpheres (0.1 µm in size) and 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine 
perchlorate (DID) (λex= 644 nm, λem= 665 nm) were purchased from Invitrogen (Merelbeke, 
Belgium). Methoxy-polyethylene glycol-amine (mPEGa) 2 kDa was purchased from Creative 
PEGWorks (Winston Salem, USA). Alexa Fluor-488 Negative Control siRNA ((Eurogentec, 
Seraing, Belgium). 
 
 
 
2.2 Animals  
Mice, heterozygous for Foxn1 (nu/+) were purchased from Charles River (Sulzfeld, Germany) and 
maintained by the animal core facility. Animals were kept at 22 °C in a humidified atmosphere 
with food and water ad libidum. 
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2.3. Collection of biofluids 
To collect samples containing mouse intraperitoneal fluid, a lavage of the peritoneal cavity was 
performed. To this end, mice were euthanized by an overdose of the inhalation anesthetic 
isoflurane followed by cervical dislocation. The abdominal wall was opened immediately and the 
peritoneal cavity was washed with 1 mL of water. The lavage was taken and stored frozen until 
use. The procedure was approved and carried out in compliance with the guidelines for animal 
experiments of Leipzig University.  
Human serum was obtained from a healthy donor. Briefly, blood was collected at the Ghent 
University Hospital into Venosafe™ 6 mL tubes containing gel and clotting activator (Terumo 
Europe™, Leuven, Belgium). Then the tubes were centrifuged for 10 minutes at 4,000 × g and 
20°C. The supernatant (serum) was transferred into microvette® 500 Z-Gel (SARSTEDT, 
Numbrecht, Germany) and centrifuged for 5 minutes at 1,0000 × g and 20°C. The serum was 
portioned into 50 µl aliquots (to avoid freezing-thawing cycles) in sterile polypropylene tubes and 
stored in -20°C until use. Human ascites fluid was obtained from a patient diagnosed with 
peritoneal carcinomatosis at the medical oncology department, Ghent University hospital. The 
experiments with the ascites fluid were approved by the ethics committee of the Ghent University 
hospital  (# 2013/589). 
 
2.4 Protein analysis and capillary electrophoresis 
Total protein in human serum, human ascites fluid, and mice peritoneal fluid was assayed using a 
pyrogallol red-molybdate method on a Cobas 8000 analyzer (Roche, Mannheim, Germany) [39]. 
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Human serum and human ascites fluid protein electrophoresis was performed using a Capillarys 
2™ CE system (Sebia, Paris, France) that is routinely employed in clinical laboratories [40, 
41]. Prior to the hydrodynamic injection (4”), 40 µl of serum is automatically diluted 5x in the 
running buffer (pH 10).  Then, 7 kV is applied in the 8 silica-fused capillaries (effective 
length 15.5 cm; internal diameter 25 µm; optical cell 100 µm) for 4’ at 35.5°C (Peltier 
device). Proteins are detected at the cathode (deuterium lamp; 200 nm) as 5 fractions (γ-globulins, 
β-globulins, α2-globulins, α1-globulins and albumin) that are automatically quantified as 
percentages of the total signal. 
For mice peritoneal fluid (characterized by low protein concentrations), agarose gel 
electrophoresis was carried out, followed by a sensitive staining using the Protur HiSi 100 system 
(Analis, Suarlée, Belgium).  
2.5 Viscosity measurements  
Viscosity measurements of human ascites fluid and human serum were performed using a micro-
Ubbelohde viscosimeter (53610/I) (Schott-Geräte (Mainz, Germany)) at 22°C. 4 mL of each bio 
fluid were loaded on a capillary (ID number 100-002 with capillary constant K= 0.009671 mm2/s2) 
and the flow time (in seconds) was measured 3 times for each biofluid. The averaged flow time 
was used to calculate the kinematic viscosity according to the following equation:  
ν = K× (t-y) 
where t is the averaged flow time, and y (in seconds) is the kinetic energy correction for the flow 
time provided by the manufacturer. For human serum, the calculated kinematic viscosity is 1.6 
mm2/s and for the human ascites fluid is 1.39 mm2/s. The dynamic viscosity η is defined using  
the following relation: 
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η = ρ × ν 
Where η is the density of fluid (g/mL) and 1 cSt = 1 mm2/s . Since the density of human serum 
and human ascites fluid is very close to 1 g/mL [42], we assume all the densities of fluids used in 
this study are equal to 1, and thus in all Single Particle Tracking measurements the following 
values of dynamic viscosity were used:  1.39 cP for human ascites fluid, 1.6 cP for human serum, 
and 0.94 cP for mice IP fluid and HEPES buffer.  
2.6 Functionalization of anionic polystyrene nanoparticles  
Functionalization of 100 nm anionic nanoparticles to PEGylated and positively charged ones was 
performed according to previously published procedures [43]. The charge and size of the 
nanoparticles was measured using the Zetasizer Nano-ZS (Malvern, Worcestershire, UK). The 
average size of all the nanoparticles in HEPES buffer (pH 7.4) was around 110 nm, and zeta-
potential around 30 mV for the positively charged nanoparticles, -13 mV for the PEGylated 
nanoparticles, and around -33 mV for the anionic nanoparticles.  
2.7 Preparation of liposomes 
DOTAP and DOPE lipids were dissolved in chloroform and mixed in a round bottomed flask. A 
lipid film was formed by rotary evaporation of the chloroform at 40°C. The dried lipid film was 
rehydrated with 20 mM HEPES buffer pH 7.4, resulting in a final concentration of 5 mM DOTAP 
and 5 mM DOPE. Thereafter, liposomes were sonicated using a probe sonicator (Branson 
Ultrasonics Digital Sonifier®, Danbury, USA). For the preparation of PEGylated liposomes, the 
desired amounts of DSPE-PEG dissolved in chloroform (corresponding to 5 mol% or 10 mol% of 
the total lipids) were added to the lipids in the round bottomed flask before evaporation. For SPT 
experiments, liposomes were fluorescently labeled by incorporation of 1 mol% (of the total lipids) 
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with DID. The average size and zeta potential of the liposomes was measured using Zetasizer 
Nano-ZS (Malvern, Worcestershire, UK).  The average diameter of the liposomes was around 90 
nm for the cationic liposomes and 100 nm for the PEGylated ones. The zeta potential around + 45 
mV for the cationic liposomes, 15 mV for  the 5 mol% PEGylated liposomes and 7 mV for the 10 
mol% liposomes.  
2.8 Size and zeta-potential measurements  
The average size and the zeta potential of the liposomes and the polystyrene nanoparticles were 
measured using the Nano-ZS Zetasizer (Malvern, Worcestershire, UK) in 4 different biofluids: 
HEPES buffer, mice IP fluid, human ascites fluid, and human serum. Equal volumes of 
respectively cationic, 5% PEGylated and 10% PEGylated liposomes and biofluids were mixed and 
incubated for 1 hour at 37°C. At the end of the incubation period, these mixtures were diluted with 
20 mM HEPES buffer to a final concentration of 125 µM DOTAP ( ~2.5 vol% of biofluids). The 
size and zetapotential measurements were performed at 25°C. The size and the zeta potential of 
the PS nanoparticles were determined following the same procedure.  
2.9 Fluorescence single particle tracking (SPT) 
Single particle tracking (SPT) is a fluorescence microscopy technique that uses widefield laser 
illumination and a fast and sensitive CCD camera to record high speed movies of individual 
diffusing particles in  biofluids. Thereafter, the movies are analyzed by a specific image processing 
algorithm to obtain the motion trajectories for all individual particles. The trajectories are then 
used to calculate the diffusion coefficient of each particle. After analyzing many particles, a 
distribution of diffusion coefficients is obtained which is transformed into size distribution using 
the Stokes-Einstein equation and refined by the maximal entropy method (MEM), as previously 
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described [36]. The conversion of diffusion coefficients to sizes requires knowledge of the 
viscosity of the biofluid and the temperature at which the experiment is performed.  
SPT measurements on different PS nanoparticles (Anionic, PEGylated, Cationic) and DID labeled 
liposomes dispersed in biofluids were performed as follows. First, formulations were diluted 400 
times in HEPES buffer. Then 5 µl was added to 45 µl of biofluid (e.g. 90 vol% of mice IP fluid, 
human ascites fluid and human serum), and incubated for 1 hr at 37°C in a 96-well plate (Greiner 
bio-one, Frickenhausen, Germany). At the end of the incubation time,  the sample was placed on 
the custom-built SPT set-up [36] and movies were recorded focused at about 5 μm above the 
bottom of the glassbottom 96-well plate. Videos were recorded at room temperature (22.5°C) with 
the NIS Elements software (Nikon) driving the EMCCD camera (Cascade II:512, Roper Scientific, 
AZ, USA) and a TE2000 inverted microscope equipped with a 100× NA1.4 oil immersion lens 
(Nikon). Analysis of the videos was performed using in-house developed software. During the 
incubation and measurements, the well plate was covered with Adhesive Plates Seals (Thermo 
Scientific, UK) to avoid evaporation of the sample and allow diffusion only.         
 
 
2.10 FCS on siRNA containing liposomes (lipoplexes)  
FCS is a microscopy-based technique that monitors the fluorescence intensity fluctuations of 
molecules diffusing in and out of the focal volume of a confocal microscope. Shortly, when free 
siRNA molecules are present in the focal volume, a fluorescence signal (baseline) is obtained 
which is proportional to the local siRNA concentration. When the siRNA is complexed with 
nanoparticles, the concentration of free siRNA (e.g. the baseline) drops and peaks of high 
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fluorescence intensity appear each time a nanocomplex containing many fluorescent siRNA 
molecules passes the detection volume. Vice versa, when siRNA dissociates from the complexes, 
the concentration of free siRNA increases again, resulting in an increase of the baseline. The 
drop/increase in the intensity of the baseline can be used to calculated the percentage of the 
complexed/released siRNA as was previously described by Buyens et al. [38]. Single color FCS 
measurements were performed on lipoplexes containing Alexa-488 siRNA Negative Control 
siRNA ((Eurogentec, Seraing, Belgium). To follow the release of the complexed siRNA in 
function of time, lipoplexes with +/- charge ratio of 8 were prepared by adding appropriate 
amounts DOTAP DOPE liposomes to siRNA. The mixture was then incubated at room 
temperature for 30 minutes to allow formation of the lipoplexes. The size of the lipoplexes was 
measured using dynamic light scattering and was about 100 nm for cationic ones and 110 nm for 
the PEGylated. For FCS measurements, 5 µl of the lipoplexes were diluted in 45 µl of each biofluid 
(resulting in 90 vol% of mice IP fluid, human ascites fluid and human serum in the final samples) 
and the fluorescent signal was measured respectively immediately after mixing the lipoplexes with 
the biofluids and after one hour of incubation at 37°C. During the incubation and the FCS 
measurements, the well plate was covered with Adhesive Plates Seals (Thermo Scientific, UK) to 
avoid evaporation of the sample and to minimize flow.  
FCS measurements were performed on C1si laser scanning confocal microscope (Nikon, Japan), 
equipped with a Time-Correlated Single Photon Counting (TCSPC) Data Acquisition module 
(Picoquant, Berlin, Germany). The laser beam was held stationary and was focused through a water 
immersion objective lens (Plan Apo 60×, NA 1.2, collar rim correction, Nikon, Japan), at about 50 
μm above the bottom of the glassbottom 96-well plate (Grainer Bio-one, Frickenhausen, 
Germany), which contained the fluorescent samples (free Alexa488-siRNA and Alexa488-siRNA  
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complexed to non-PEGylated, 5% PEGylated or 10%  PEGylated liposomes (5 nM Alexa488-
siRNA in all samples)). The 488 nm laser beam of a krypton–argon laser (Bio-Rad, Cheshire, UK) 
was used and the green fluorescence intensity fluctuations were recorded using Symphotime 
(Picoquant, Berlin, Germany) during at least 60 seconds.   
3. Results  
3.1 Protein content of the biofluids   
The data in table 1 depicts the total protein content in each  biofluid. The highest protein content 
was determined in the human serum samples obtained from a healthy donor. Ascites fluid from 
the peritoneal cavity of a patient diagnosed with peritoneal carcinomatosis contained almost half 
the amount of proteins when compared to human serum. Peritoneal fluid extracted from mice was 
found to contain a rather low protein concentration. This most likely can be attributed to the 
collection procedure in which the peritoneal fluid of mouse if diluted between 10-50 times at least, 
unlike the human serum and ascites fluid, where the collection procedure did not involve any 
dilution. With regard to the type of proteins found in each sample, capillary electrophoresis of the 
human serum and ascites fluid reveals a very similar composition, with a major fraction of albumin 
(Fig. 1A, Fig. 1B). Also mouse peritoneal fluid contains a major albumin fraction (68 KDa) and a 
prominent transferrin fraction (80 KDa) (Fig. 1C).  
 It should be noted that in the case of peritoneal carcinomatosis, the high protein content observed 
in the ascites fluid is attributed to the increased permeability of the peritoneal membrane induced 
mainly by vascular endothelial growth factor (VEGF) [44]. In patients with an earlier stage of 
peritoneal carcinomatosis, the total amount of proteins present in the peritoneal fluid is expected 
to be less. Nevertheless, a relative protein composition, similar as in figure 1B is expected. 
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3.2 Colloidal stability of PS nanoparticles and liposomes in diluted  peritoneal fluids and serum 
The data in Fig. 2. demonstrate the size and the zeta-potential of PS nanoparticles measured by 
DLS following 1 hr of incubation at 37°C in each of the studied biofluids. Samples were incubated 
in 50 vol% of biofluids and further diluted to 2.5% biofluids for the actual measurements. As 
illustrated in  Fig. 2A. (note the broken axis), cationic nanoparticles (white bars) show pronounced 
aggregation in biofluids with a low protein concentration and less aggregation in biofluids with a 
high protein content. This aggregation is accompanied by a significant decrease in the zeta 
potential: the positively charged nanoparticles (+ 28 mV) in HEPES buffer turn negative upon 
dispersing them in the biofluids (Fig. 2B.). Interestingly, an “opposite” aggregation pattern was 
observed with the anionic nanoparticles (dark grey bars), whose state of aggregation seemed to be 
correlated with the protein content of the biofluids. Yet, when compared to cationic polystyrene 
nanoparticles, this aggregation was less pronounced. Notably, the zeta potential of the anionic 
nanoparticles increases from -33 mV in HEPES buffer to less negative nanoparticles in the rest of 
the biofluids. The size of the PEGylated nanoparticles (Fig. 2A. grey bars) did not change upon 
incubation in the biofluids, indicating that the PEG-chains effectively inhibit aggregation.   
 
As liposomes are widely used in drug delivery and hold potential for siRNA delivery in the 
peritoneal cavity, it is of interest to have an insight on the aggregation profile of different liposomal 
formulations in IP fluid. Therefore, we investigated the colloidal stability upon incubating non-
PEGylated, 5% PEGylated and 10% PEGylated liposomes in the biofluids. The data in Fig. 3. 
show the hydrodynamic diameter and the zeta potential of cationic and PEGylated liposomal 
formulations following 1 hr of incubation in the biofluids.  It can be seen that the extent of 
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aggregation (Fig 3A, broken axis) is more severe in human serum > ascites fluid > mice IP fluid 
which correlates with the protein content of the biofluids (table 1).  In particular, the aggregation 
is the most pronounced for the cationic liposomes (white bars), while  PEGylation significantly 
diminishes aggregation of cationic liposomes, indicating that the PEG chains improve the colloidal 
stability of the cationic liposomes. As can be seen from Fig. 3B, a drop in the zeta potential was 
observed for all the liposomal formulations upon dispersing them in the biofluids (especially in 
human serum and ascites fluid).  
 
3.3 Aggregation of PS nanoparticles and liposomes in undiluted biofluids 
Dynamic light scattering (DLS) is the most common technique to measure the average size of 
nanoparticles in aqueous media. However, measuring the size of nanoparticles in biofluids by DLS 
is challenging as proteins in the biofluids can scatter the light and interfere with the measurements. 
As an example size distributions of the biological fluids only diluted in HEPES buffer are shown 
in Supplemental Fig. 1 A and  Fig. 1 B. Therefore, the DLS measurements in the previous sections 
were performed on highly diluted samples (only 2.5 vol% of biofluids in Fig. 2 and Fig. 3).  
 We have previously shown that SPT is a powerful technique to measure the size of 
nanoparticles in undiluted biofluids such as serum and blood [36, 45, 46]. Here, we present for the 
first time the aggregation behavior of nanoparticles in undiluted intraperitoneal fluids, and 
compared the aggregation profile with the one obtained in buffer and human serum. A particular 
benefit of SPT is that size measurements are performed on a per particle basis so that, contrary to 
DLS, there is no bias towards larger sizes. 
 The size distributions of the PS nanoparticles, as obtained by SPT in undiluted biofluids, 
are depicted in Fig 4.  In line with the DLS data (Fig 2A), on average 100 nm size particles are 
16 
 
observed in HEPES buffer. In the biological fluids, particles sizes increase to about 200 nm in 
human serum, 300 nm in ascites fluid and even µm sized aggregates in mice IP fluid, again 
confirming the DLS results. For the anionic nanoparticles (Fig 4B), a different aggregation pattern 
was observed: only a slight increase in size was noticed for the ascetic and mice IP fluid, while a 
broadened distribution was observed in human serum. In the case of PEGylated nanoparticles (Fig. 
4C.), the particles remained stable in mice and ascites IP fluid. Also, human serum resulted only 
in a very minor increase in size compared to the buffer sample. These findings are all consistent 
with the trends observed by DLS (Fig. 2A).  
The aggregation behavior of the liposomes dispersed in the undiluted biofluids is shown in Fig. 5 
and Fig. 6. For the cationic liposomes, large non-diffusing aggregates (up to 2-3 µm) in size were 
observed at the bottom of the well following 1 hr of incubation in mice IP fluid, ascites fluid and 
human serum (Fig. 5). As these aggregates did not show Brownian motion, SPT data could not be 
obtained. The size distributions of the 5% PEGylated liposomes (Fig. 6A) confirm the outcome of 
the DLS data in Fig. 3A, and show the profound aggregation of these liposomes in human serum. 
In the mice IP fluid and ascetic fluid, this aggregation is less prominent. Finally, the 10% 
PEGylated liposomes hardly aggregate in the peritoneal fluids. In human serum, at least a part of 
the liposomes did not aggregate as can be seen from the bimodal behavior. Note that the size 
distribution for the 10% PEGylated liposomes in HEPES buffer seems broader than the one for 
the 5% PEGylated liposomes. Possibly, this is due to the structure the liposomes adopt with higher 
degrees of PEGylation, including small disks and large aggregates which contribute to the 
polydispersity of the sample [47].  
3.4 Release of siRNA from liposomes in undiluted biofluids 
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siRNA has the potential to treat peritoneal metastasis by preventing the growth and spread of 
circulating tumor cells. For siRNA to be biologically active, it needs to reach the cytoplasm of the 
tumor cells. Therefore, it is generally ‘complexed’ with cationic carriers such as polymers or 
liposomes, as ‘naked’ siRNA is not taken up by cells. In the next set of experiments, we aimed to 
determine the stability of siRNA-liposome complexes in peritoneal fluids, with respect to siRNA 
release from the formulations. When siRNA is prematurely released from the complexes in the 
biofluids, the biological activity will be lost. The percentage of free siRNA in HEPES buffer at the 
zero hour time point (Fig 7A, grey bars), shows the amount of siRNA that remained free (e.g. 
uncomplexed) when the siRNA/liposome complexes were formed. About 2%, 6% and 15% of 
siRNA is not encapsulated in respectively the cationic, 5% PEGylated and 10% PEGylated 
liposomes. This indicates that a higher PEGylation degree lowers the siRNA encapsulation 
efficiency. Following 1 hr of incubation, the effect of PEGylation becomes even more pronounced: 
only the non-pegylated liposomes retain the complexed siRNA. For the 5% and 10% PEGylated 
liposomes, respectively 30% and even 85% of siRNA is released into HEPES buffer. Next, the 
siRNA containing complexes were incubated with the undiluted biofluids.  When compared to 
HEPES buffer (Fig 7A, grey bars), we observe an immediate release of siRNA at the zero time 
point upon dispersing the complexes in the biofluids (Fig 7, B-D, grey bars). This immediate 
release most likely corresponds to the release of surface-bound siRNA and increases with 
PEGylation degree. Further incubating the complexes in the biofluids for 1 hour did not result in 
a substantial additional release of siRNA (Fig 7B-D, white bars), except for the 5% PEGylated 
complexes in human serum (Fig 7D, white bars). Overall, the siRNA release was limited to 
maximally 30% for the cationic liposomes, while for the 5% and 10% PEGylated liposomes, 
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between 65-80% of siRNA was released into the peritoneal fluids and even close to 100% siRNA 
was released in human serum after 1 hour.  
 
4. Discussion 
Designing new delivery systems for targeting peritoneal cancer cells is a major challenge. Apart 
from the IV route of administration, intraperitoneal (IP) delivery of nanoparticles that target cancer 
cells over a prolonged period of time is being explored. Upon IP delivery, nanoparticles are directly 
administered at the target site. Hence, interactions of the nanoparticles with blood components that 
potentially induce immune responses or stability issues could be avoided [48]. The stability of 
nanoparticles in the IP fluid is a major determinant for their efficacy. Indeed, both particle 
aggregation or premature release of cargo in the IP fluid could diminish the biological effect. The 
colloidal stability of nanoparticles in IP fluids has, however, not been studied in detail before. In 
this study, we employed advanced microscopy techniques to directly assess stability of 
nanoparticles in terms of aggregation and cargo release, in undiluted  biofluids such as mice IP 
fluid and ascites fluid from a patient diagnosed with peritoneal carcinomatosis and compared it to 
human serum.    
 4.1 Aggregation of model PS nanoparticles and liposomes in peritoneal fluids 
Aggregation of different PS nanoparticles and liposomal formulations in the peritoneal fluids was 
tested using DLS and SPT. Two main questions were addressed, namely: (1) does the 
physicochemical properties of the material (e.g. charge and PEGylation degree) influence 
aggregation and (2) does the concentration of the proteins in each of the biofluids correlate with 
the aggregation profiles?  
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PS nanoparticles were used in this study as an inert hydrophobic model system. Liposomes, 
on the other hand, are frequently used to deliver therapeutic agents to target cells. A summary of 
their aggregation profiles can be found in Table 2. It was already demonstrated before that serum 
induces quick aggregation of positively charged nanoparticles [36]. This was confirmed in our 
study, especially for the positively charged liposomes. Also in mice and human IP fluid, severe 
aggregation of positively charged particles was observed. As seen in Fig 1., albumin is the major 
protein fraction in both mice and human IP fluid, as well as in human serum (~60%). Under 
physiological conditions (pH 7-7.4) albumin and other negatively charged proteins are capable of 
binding to cationic nanoparticles, inducing the formation of micrometer sized protein-
nanoparticles complexes [31]. It is thus most likely that albumin is the most abundant component 
in the protein corona around the positively charged nanoparticles, as was observed before [49]. 
The formation of protein-nanoparticle complexes also explains the drop observed in the zeta 
potential in Fig. 2A. and Fig. 2B. It should be noted that negatively charged nanoparticles tend to 
bind proteins with an isoelectric point greater than 5.5, such as IgG [50]. This explains why the 
zeta potential of the negatively charged polystyrene beads becomes less negative upon incubation 
with the biofluids.   
The adsorption of proteins to the nanoparticles described above is drastically diminished 
when the surface of the PS nanoparticles and  liposomes is decorated with PEG (table 2). Despite 
the role of PEG in avoiding aggregation, the data presented in Fig. 6B indicate that there is a limit 
to which extent the protein adsorption could be prevented. This finding is significant, suggesting 
that 10% PEGylated liposomes are very stable in the peritoneal fluids, but not in human serum 
where aggregation still takes place due to the high density of proteins bound on the surface of the 
PEG residues (Table 1). In general, it seems that PEGylation is necessary to avoid the formation 
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of aggregation in peritoneal fluids. Both positively and negatively charged non-PEGylated 
nanoparticles tend to form large aggregates upon incubation with peritoneal fluids or human 
serum. 
 Among all the studied formulations the aggregation tendency seemed proportional to the 
protein concentration of the incubation fluid, except for positively charged PS NPs, which show 
the greatest aggregation in mice IP fluid with lowest protein content. The exact reason for this is 
unclear. It should be noted, however, that the positively charged PS NPs become negatively 
charged upon incubation with the biofluids. The negatively charged PS NPs, on the other hand, 
become slightly less negative. Therefore, the actual proteins that bind to the NPs are expected to 
be different for cationic or anionic NPs, respectively, which might influence their aggregation 
behavior. Another observation is that the liposomes tend to aggregate more than PS NP in all 
biofluids. This most probably stems from the intrinsic properties of the building blocks. In 
particular, when collisions between two liposomes occur (especially non-PEGylated ones), 
hydrophobic interactions between lipids from both liposomes can take place, supporting the 
formation of aggregates. On the contrary, PS NP are ‘inert’ plastic particles that could ‘bounce’ 
upon collision and shown no additional attracting forces that would support the formation of 
aggregates.  
4.2 Release of siRNA from liposomes in the peritoneal fluids 
Apart from colloidal stability in terms of aggregation, the nanoparticles should be able to bring 
their cargo to the target site. The release of siRNA from liposomal formulations in the peritoneal 
fluids was evaluated using Fluorescence Correlation Spectroscopy (FCS). As we previously 
demonstrated, FCS is an elegant technique to follow the complexation behavior of small nucleic 
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acids to nanoparticles, both in buffer and in living cells [38, 51]. The data in Fig 7. clearly suggest 
better complexation and slower release of siRNA for the non-PEGylated lipoplexes over the 
PEGylated ones. The higher the PEGylation degree, the more rapid the siRNA molecules 
dissociate from the complexes, even in buffer conditions. This most likely stems from the proposed 
mechanism for lipoplex formation [52-54]. When cationic liposomes are added to negatively 
charged siRNA, strong electrostatic interactions occur, and the majority of the siRNA molecules 
attach to the surface of the liposomes. These siRNA-coated liposomes can subsequently fuse with 
other liposomes, so that siRNA is entrapped within the bilayer of the liposomes. In the case of 
PEGylated lipoplexes, the PEG chains prevent the fusion of different liposomes, resulting in 
lipoplexes in which siRNA is only bound to the outer surface and not “sandwiched” in between 
the multilayers of the liposomes. Also, the lower surface charge leads to less complexation, 
resulting in an increasing amount of free siRNA at zero time with higher degree of PEGylation as 
seen in Fig 7.    
The release is also dependent on the composition of the biofluid in which the lipoplexes were 
incubated afterwards. For the PEGylated lipoplexes, the excess of albumin and other negatively 
charged proteins triggers the release of the surface bound siRNA from the complexes by competing 
for binding to the cationic lipids. In human serum, the release percentage of the siRNA is the 
highest when compared to other biofluids, as these samples contain the highest protein 
concentration. Interestingly, only small differences occur in the percentages of release of siRNA 
from non-PEGylated lipoplexes in between zero time and 1 hr of incubation in the different 
biofluids. This shows that negatively charged proteins in serum and IP fluids only compete with 
siRNA bound to the surface of the lipoplexes, leaving siRNA sandwiched in between the lipid 
bilayers unaffected.   
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4.3 Tailoring delivery systems for IP therapy 
Nano-sized delivery vehicles for IP administration for the treatment of ovarian cancer and 
peritoneal carcinomatosis should meet several efficacy and safety requirements: (1) long retention 
time in the peritoneal cavity to ensure maximal therapeutic efficiency, (2) limited leakage into the 
systemic circulation to avoid toxic side effects, (3) a specific targeting of tumor cells and (4) 
limited immune and inflammation responses. All these are still major challenges in IP delivery 
systems [22].  
 Fig. 8. schematically represents the different steps and hurdles for nanoparticles 
administered to the IP cavity. In the case of siRNA, internalization of the carrier into the cells is 
needed, before knock down of proteins responsible for the proliferation of cancer cells can occur. 
The data presented in this study undoubtedly propose rapid aggregation of positively and 
negatively charged nanoparticles in the peritoneal fluids. Large size aggregates, however, are not 
efficiently taken up by cells anymore. Therefore, the siRNA activity of these aggregates will be 
lost (Fig. 8A., step 1). Also, premature release of siRNA from the carrier in the peritoneal fluid is 
not desired (Fig. 8A., step 2) as free siRNA is not able to penetrate into the cytosol of the cancer 
cells. While reduced aggregation is achieved by PEGylation of nanoparticles, the PEGylated 
liposomes suffered from a fast release of the complexed siRNA upon exposure to the IP fluids. 
Also, PEGylation has been associated with low transfection efficiency due to poor uptake and/or 
interaction with the endosomal membrane. Nevertheless, different PEGylation strategies can be 
exploited to prevent aggregation, while keeping the transfection efficiency [55]. An interesting 
strategy is the use of sheddable PEG-chains that protect the nanoparticles from aggregation in the 
extracellular environment, but dissociate once the nanoparticles enter certain intracellular 
compartments. Also, altering the formation procedure of liposomes is an option. By hydrating the 
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lipid film with a solution of siRNA at least part of the loaded siRNA is entrapped inside the 
liposomal core, even when PEGylated liposomes are used [56]. Also post PEGylation of preformed 
siRNA/liposome formulations (in which all siRNA is entrapped between lipid bilayers) is feasible. 
Apart from aggregation and premature cargo release, the clearance of nanoparticles from the 
peritoneal cavity is an important parameter. Ideally, nanoparticles should reside in the IP cavity as 
long as possible, without leakage into the systemic circulation (Fig. 8B., step 4). It has been 
suggested, however, that nanoparticles are cleared from the peritoneal cavity within 2 days [57]. 
Therefore, for developing RNAi-based therapy for the treatment of peritoneal cancer (which 
preferentially makes use of nano-sized particles for optimized cell internalization), a future 
strategy could be to load nanoparticles into a sustained release system. Taking into account the 
clearance rate of nanoparticles from the IP cavity, such a controlled release system can be tuned 
so  that a constant amount of nanoparticles is present in the IP cavity. It should be noted that a 
good retention time in the peritoneal cavity was reported for 100 nm positively charged liposomes 
by Dadashzadeh et al. [58]. The size of the liposomes upon IP administration was however not 
continuously monitored. In our opinion, this slower clearance rate can be attributed to the 
aggregation of these nanoparticles to micrometer sized particles in the IP fluid. As has been 
suggested, these microparticles do indeed show a slower clearance rate from the IP cavity when 
compared to nanoparticles [59].  
 
 Unlike for siRNA, conventional anti-cancer agents such as paclitaxel and doxorubicin 
(DOX) do not need a carrier system to be taken up in cells. Therefore, the aggregation of 
nanoparticles or premature cargo release might not be a major problem for these type of 
formulations (Fig. 8B). Aggregation of nanoparticles would however lead to large size aggregates 
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which could lead to increasing difficulty of drug dissolution in the IP fluid (Fig 8B, step 1). Also, 
Kohane et al. concluded that microparticles do not appear to be good candidates for IP drug 
delivery due to the risk of adhesions [57]. Also, a disadvantage of the conventional cytostatics, is 
the non-specificity of the drugs which also affect healthy-non tumor cells and the fact that tumor 
cells can develop resistance after long-term treatment and exposure.    
  It should be noted that the environment of the peritoneal cavity seems to be less aggressive 
than the one of the systemic circulation: while 5% PEGylated liposomes remained stable in IP 
fluid, aggregation was still observed in the human serum. Therefore, one could argue that less 
colloidal stable nanoparticles could still be used for IP administration. We have the opinion, 
however, that IP administered nanoparticles should also be stable enough in the systemic 
circulation, since clearance of these particles from the peritoneal cavity to the systemic circulation 
is most likely inevitable (Fig, 8, step 4). When a colloidal stable nanoparticle, once it leaves the IP 
cavity, starts aggregating in the blood circulation, there is a risk of clogging blood capillaries, 
which should obviously be avoided.   
Finally, it is important to stress out that the outcomes from the stability testing in vitro in biofluids 
with the techniques used in this study (FCS and SPT) represent a good prediction of the stability 
for the in vivo situation. Therefore, formulations that are not stable enough in vitro should not be 
considered for in vivo applications. Rather, further in vitro optimization should take place to 
enhance the stability of nanoparticles and to ensure that only stable formulations are used for 
further animal studies. It should be noted, however,  that the in vivo situation is expected to be 
more complex than the in vitro one in biological fluids. Therefore, particles that showed good 
stability in the biofluids should always be further tested in vivo to determine their biological 
activity.  
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5. Conclusions 
There is increasing interest from clinicians in treating carcinomatosis patients with some form of 
IP therapy. Unfortunately, none of the currently used drugs in this setting have been specifically 
designed or tested for IP application. In this study, for the first time, we investigate the aggregation 
and release of cargo from nanoparticles in peritoneal fluids. Our data indicate fast aggregation of 
positively and negatively charged nanoparticles in the peritoneal fluids, which can be prevented 
by decorating the surface with PEG. Conventional complexation of nucleic acids with our 
PEGylated liposomes results however in a rapid release of the nucleic acids in the peritoneal fluids, 
which is not preferred.  
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